Access to Long-Acting HIV Prevention Drug Delayed in England

In what has been called a severe blow to HIV prevention, England is experiencing some delays in providing access to a very important, long-acting HIV prevention drug. The drug, known as cabotegravir, is injected once every two months and thus represents another option than the pills available that are taken daily. This new treatment has been hailed as a game-changer in the fight against HIV because it reduces the onus of having to take medication frequently and thus improves adherence rates.

Continue reading